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Background: Neuroblastic tumors are often addicted to the MYCN protooncogene.
Results: Using a genome wide shRNA screen, we have identified key MYCN synthetic lethal genes.
Conclusion: Chemical inhibition of the newly identified MYCN synthetic lethal genes selectively kills MYCN-amplified cell
lines.
Significance: Decoding the MYCN gene network will help to develop drugs for the treatment of neuroblastic tumors with
activated MYCN.
TheMYC family of transcription factors consists of three well
characterized members, c-MYC, L-MYC, and MYCN, deregu-
lated in themajority of human cancers. In neuronal tumors such
as neuroblastoma,MYCN is frequently activated by gene ampli-
fication, and reducing its expression by RNA interference has
been shown to promote growth arrest and apoptosis of tumor
cells. From a clinical perspective, RNA interference is not yet a
viable option, and small molecule inhibitors of transcription
factors aredifficult todevelop.We thereforeplanned to identify,
at the global level, the genes interacting functionallywithMYCN
required to promote fitness of tumor cells facing oncogenic
stress. To find genes whose inactivation is synthetically lethal to
MYCN, we implemented a genome-wide approach in which we
carried out a drop-out shRNA screen using a whole genome
library that was delivered into isogenic neuroblastoma cell lines
expressing or not expressing MYCN. After the screen, we
selected for in-depth analysis four shRNAs targeting AHCY,
BLM, PKMYT1, and CKS1B. These genes were chosen because
they are directly regulated by MYC proteins, associated with
poor prognosis of neuroblastoma patients, and inhibited by
small molecule compounds. Mechanistically, we found that
BLM and PKMYT1 are required to limit oncogenic stress and
promote stabilization of the MYCN protein. Cocktails of small
molecule inhibitors of CKS1B, AHCY, BLM, and PKMYT1 pro-
foundly affected the growth of all neuroblastoma cell lines but
selectively caused death ofMYCN-amplified cells. Our findings
suggest that drugging theMYCNnetwork is a promising avenue
for the treatment of high risk, neuroblastic cancers.
There are three well characterized members of the MYC
family in mammalian cells, c-MYC, MYCN, and L-MYC
(defined hereafter as MYC). Other less studied members are
S-MYC and B-MYC. They interact with DNA through a con-
sensus sequence called the E-box (CANNTG) and in concert
with the partnerMAX facilitate gene transcription. Experimen-
tal evidence indicates that MYC and MYCN are functionally
interchangeable, with MYCN having a more restricted spatial
and temporal role during development (1). The importance of
MYC in cell biology is vast.MYCcontrols key cellular processes
including: regulation of cell death (2, 3), angiogenesis (4, 5),
metabolism (6), chromatin remodeling (7, 8), and generation of
pluripotent stem cells (9).MYCmembers are proto-oncogenes:
on a par with p53 mutation, MYC activation is the most fre-
quent molecular alteration observed in human cancer (2). How
MYC mechanistically brings about all these functions is still a
matter of study, but its classical role as transcriptional activator
is being revised in the light of evidence suggesting that MYC is
able to modify the chromatin by direct and indirect cross-talk
to chromatin modifiers, for example DNAmethyl-transferases
(7). Along this line, we and others have recently observed that
MYCs inhibits the transcription of tumor suppressor genes or
microRNAs by physically recruiting the polycomb-repressive
complex 2 to promoters in the proximity of MYC-binding sites
(10–12). This demonstrates that MYC recruits co-repressor
molecules in a sequence-specificmanner to inducemethylation
of histone H3 on lysine 27 and transcriptional repression of
specific genes. Given the importance of MYC in the biology of
cancer, many clinical researchers are trying to develop drugs
that inhibit its activity. Although small molecule inhibitors of
MYC are difficult to develop, a dominant-negative variant of
MYC, called omomyc, has shown anticancer effects in vivo,
validating the hypothesis that targeting MYC is highly relevant
(13). However, the protein omomyc is unlikely to be used in
patients; thus further research is needed to develop clinically
viable MYC-targeting drugs. An alternative approach to MYC
targeting is to develop drugs that inactivate key MYC partners.
For example, it has been shown that MYC-dependent tumors
are sensitive to inhibitors of BET family chromatin adaptors
and containing bromodomains such as BRD4, required for
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transcriptional elongation of MYC (14, 15). Furthermore, we
and others have shown that inhibiting the MYCN associate
EZH2 or other enzymes that modify the chromatin landscape
causes reactivation of CLU and other potential tumor suppres-
sor genes in cancer cells with therapeutic effects (16–18). This
indicates that blocking chromatinmodifiers could be of clinical
value inMYCN-overexpressing tumors such as neuroblastoma.
Neuroblastoma is the most common extracranial solid
tumor in childhood and one of themajor causes of cancer death
in infancy. Neuroblastoma originates from cells of the neural
crest, the embryonal structure that forms the peripheral nerv-
ous system. Clinically, we distinguish two types of neuroblas-
toma: a localized form, usually benign, and a high risk, meta-
static form. High risk neuroblastoma has very poor prognosis,
and the survival rate after 5 years is only40% despite chemo-
and radiotherapy (19). Indeed, metastatic neuroblastoma
shows initial response to therapeutic interventions but typically
relapses into an incurable form of the disease. It is notable that
in the past 20 years there has been no substantial improvement
in the outcome of high risk neuroblastoma, suggesting that new
avenues of therapy are urgently needed. When activated by
amplification in a fraction (30%) of neuroblastomas, the pro-
tooncogeneMYCN is a direct cause of the disease. Transgenic
expression of MYCN in the neuroectoderm causes neuroblas-
tomas in mice with features similar to those seen in the human
disease (20). Conversely, inhibition of MYCN by antisense
approaches results in neuroblastoma regression in vivo and in
vitro (21). Collectively these results demonstrate thatMYCN is
a key driver of tumorigenesis in neuroblastoma, suggesting that
therapeutic efforts aimed at inhibiting its expression/activity
should have an important clinical relevance.
Activation of MYC imposes an oncogenic stress to tumor
cells that respond by increasing the expression of genes that
enhance cell fitness. The intricate network of genes sustaining
the oncogenic activity ofMYC, the MYC network, if identified,
could lead to the development of drugs for cancer therapy. To
identify theMYCNnetwork in neuroblastomawe used a global,
genome-wide approach in which we carried out an shRNA
drop-out screen in isogenic cell lines expressingMYCN or not.
The prediction was that the introduction of the shRNAs target-
ing the MYCN network should trigger synthetic lethality in
a MYCN-dependent manner. A similar approach has been
recently used to identify shRNAs synthetic lethal to c-MYC-
overexpressing cells in breast cancer and fibroblasts (22, 23). In
another study, the laboratory of Martin Eliers has identified,
after the analysis of 97MYCNtarget genes, AuroraA as a kinase
critically required to stabilize MYCN and whose inhibition by
small molecules has a strong impact on MYCN-driven tumors
(24, 25).
We describe here the identification of 536 genes whose
knockdown is synthetically lethal to MYCN-overexpressing
cells. To prioritize candidates, we selected for further analyses
genes whose products are inhibited by small molecule drugs,
are direct targets of MYCN, and predict poor survival in neu-
roblastoma patients. Using these criteria, we verified that
CKS1B, AHCY, PKMYT1, and BLM could potentially be used
as targets for the treatment ofMYCN-overexpressing tumors.
MATERIALS ANDMETHODS
shRNA Screen and Data Analysis—Seven pools of 9,600
shRNAs were prepared from GIPZ Human Whole Genome
shRNA Library (Thermo Scientific). The shRNA screen was
carried out following published procedures (26) using a multi-
plicity of infection of 0.3 and a representation of1,000 cellular
integrations per shRNA.GIMEN-EMPTY andGIMEN-MYCN
cells were infected in triplicate with each pool and harvested at
time point 1 (T 1; 48 h after puromycin selection) and at time
point 2 (T 2; 2 weeks after time point 1). Genomic DNA from
harvested cells was isolated using a blood and cell culture DNA
mini kit (Qiagen) following the manufacturer’s protocol.
Unique barcode sequences were amplified by PCR and purified
from agarose gel using Wizard SV gel a PCR clean-up system
(Promega, Southampton, UK) following the manufacturer’s
protocol. Purified PCR products from each cell line and time
points were combined and labeled with Cy5 and Cy3 dyes,
using the Agilent genomic DNA labeling kit plus, following the
Open Biosystem protocol adapted from Agilent oligonucleo-
tide array-based CGH for genomic DNA analysis. Labeled
PCR products were then competitively hybridized to custom
microarrays containing the barcode sequences. Data extraction
was carried out using Aglient’s Feature Extraction Software.
Analysis was performed using Bioconductor (27) and Limma
(28) software. Probes that produced a signal lower than 1.5
times the mean intensity of control probes in at least two of the
three replicates were removed. To identify MYCN synthetic
lethal shRNAs, the mean log10 Cy5/Cy3 ratios of GIMEN-
MYCN replicates was compared with that of GIMEN-EMPTY
to derive the log10 ratio difference. Genes with fold change
more than 1.5 and p values less than 0.05 were considered as
potential MYCN synthetic lethal partners.
Bioinformatic Analysis—Biofunctions of the candidate
shRNAs were assessed with the IPA software (Qiagen). Fisher’s
Exact test p value was used as a scoringmethod, and the thresh-
old was set at p  0.05. The relationships of MYCN synthetic
lethal genes identified in our screenwith the three hubs ofMYC
synthetic lethal genes identified in previous studies (29) was
established using the GeneMania software. Indirect interac-
tions were extracted from Pathway commons-Reactome and
physical interactions extracted from iRefIndex collection of
databases. In silico analysis of gene expression in neuroblas-
toma patients was carried out using the databases Oncomine
and Oncogenomics following the instructions and using the
tools available at the websites.
Lentivirus Production—Lentiviruses were generated by
transfecting 5g of the pGIPZ-shRNA and packaging plasmids
pPAX and pMDG2 into HEK-293FT cells using Lipo-
fectamine 2000 (Invitrogen) following the manufacturer’s
protocol. Supernatants were harvested 48 h after transfection
and filtered through a 0.45-mm filter unit. The sequences and
codes of the pGIPZ-shRNA constructs used for shRNA knock-
down studies are illustrated in Table 1.
Cell Culture—Human embryonic kidney cells 293FT, human
Neuroblastoma cell lines SK-N-AS, SH-SY5Y, IMR-32, SK-N-
BE(2), LA-N-1, and NB19 were obtained from the American
Type Culture Collection (Teddington,Middlesex, UK). GI-M-EN
MYCN Synthetic Lethal Genes in Neuroblastoma
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cells were a kind gift from Mirco Ponzoni (Gaslini Hospital,
Genova, Italy). SMS-KCNR Neuroblastoma cells were a kind
gift fromDr. Andrew Stoker (Institute of Child Health, Univer-
sity College London, London, UK). HEK-293FT, LA-N-1, SK-
N-AS, and SH-SY5Yweremaintained inDMEMsupplemented
with 10% heat-inactivated fetal bovine serum, 2 mM glutamine,
and sodium pyruvate. IMR-32, NB19, SMS-KCNR, and
GI-M-ENwere cultured in RPMImedium1640 containing 10%
fetal bovine serum, 2mMglutamine supplementedwith sodium
pyruvate and nonessential amino acids. All cell lines were incu-
bated at 37 °C and 5%CO2. Stable cell lines expressing the indi-
cated shRNAs were generated by lentiviral transduction in the
presence of 8g/ml polybrene followed by selectionwith puro-
mycin (1–4 g/ml). For drug treatments, cells were plated at a
density of 10,000–25,000 cells in 24-well plates in triplicate.
After 24 h, the cells were exposed to Fluoxetine (10 mM),
ML216 (15mM), 3-deazaadenosine (20mM), or PD166285 (0.05
or 0.5 mM) for 24, 48, or 72 h and counted using an hemocy-
tometer or Couness Automated Cell Counter (Invitrogen) after
Trypan Blue staining. For growth assays, GIMEN-EMPTY and
GIMEN-MYCN cells were seeded into 12-well plates at 10,000
cells/well density in triplicate.
Generation of Isogenic Cell Lines Expressing MYCN—CMV-
MYCN (16) and the empty pcDNA3.1() vector were trans-
fected into GI-M-EN cells using Lipofectamine 2000 (Invitro-
gen), as described in the manufacturer’s protocol. Several
G418-resistant clones were analyzed for MYCN expression by
Western blot analysis, and the clone expressing the highest lev-
els of MYCN was selected for further experiments.
Western Blot Analysis—Neuroblastoma cells were lysed in
radioimmune precipitation assay buffer containing 50mMTris-
HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.1% sodium deoxy-
cholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate, and a
mixture of protease inhibitors (Complete, protease inhibitor
mixture tablets; Roche Diagnostics) at 4 °C for 30 min. Cell
lysates weremixedwith SDS-PAGE loading buffer, loaded onto
8–16% gradient Precise Tris-glycine precast gels (Fisher Scien-
tific) and transferred to PVDF membranes (Fisher Scientific).
The antibodies used were MYCN (sc-53993, Santa-Cruz Bio-
technology, 1:500 dilution), gamma-H2A.X (phospho S139)
(ab11174, Abcam, 1:500 dilution), Actin (sc-1616 Santa Cruz
Biotechnology, 1:500 dilution), BLM (A300–110A, Bethyl Lab-
oratories, Cambridge Bioscience, 1:1,000 dilution), PKMYT1
(4282S, Cell Signaling, 1:500 dilution), CKS1B (36-6800, Invit-
rogen 1:500 dilution), SAHH (H00000191-M07A, Abnova,
1:500 dilution), and c-MYC (phospho T58) (ab28842, Abcam,
UK, 1:200 dilution). The membranes were then incubated
with appropriate HRP-conjugated secondary antibodies: anti-
mouse IgG (NXA931, GE Healthcare, Fisher Scientific), anti-
rabbit IgG (NA934, GE Healthcare, Fisher Scientific), or
anti-goat IgG (sc-2033, Santa Cruz Biotechnology), all at
1:10,000 dilution. Antibody binding was detected by enhanced
chemiluminescence (Fisher Scientific).
Annexin V Staining—Apoptosis was detected using an
annexin V Alexa Fluor 647 conjugate antibody (640912, Bio-
Legend, Cambridge, UK) following the manufacturer’s proto-
col. Briefly, 2 106 cells were harvested and resuspended in 500
l of annexin V binding buffer (BioLegend) either with or with-
out annexin V antibody (antibody was diluted 1:100 in annexin
V binding buffer). After 1 h of incubation on ice, 10 l of a 200
g/ml DAPI solution was added to cells before the analysis
using a BD LSRII flow cytometer.
Propidium Iodide Staining and FACS Analysis—Neuroblas-
toma cells were fixed on ice with 70% ethanol, then washed
twice in phosphate-citrate buffer (0.2 M disodium phosphate
and 0.1 M citric acid), and resuspended in PBS containing 2
g/ml propidium iodide, 0.1% Nonidet P-40, and RNase fol-
lowed by analysis on BD CyAn ADP flow cytometer.
ChIPAssay—ChIP assaywas performed as previously described
(10, 30). The PCR primers used were: PKMYT1 promoter, 5-
TTATGGACCCAAACACTACGC-3 and 5-CGCCAAAAA-
TTCCAAACC-3; and BLM promoter, 5-GGCTGAAACAG-
AAGCATGG-3 and 5-TCACCCGTACCCCTCTACAC-3.
Antibodiesused inthis studywere: IgG(sc-2027,SantaCruzBiotech-
nology),GAL4(IgG2Anegativecontrol) (SantaCruzBiotechnology),
andMYCN(sc-53993, SantaCruzBiotechnology).
RESULTS
Genome-wide shRNA Drop-out Screen—The shRNA screen
was carried out using an shRNA lentiviral library following a
protocol described previously (26, 31). The library consists of
67,200 lentiviral shRNA vectors targeting 19,851 human tran-
scripts or 17,700 gene IDs. The library was divided into seven
pools, each containing9,600 lentiviral shRNA vectors. Pools
were calculated to introduce a single copy of the vector in at
least 1,000 cells (Fig. 1A). Lentiviral pools were used to infect
the control orMYCN-expressingGIMENcell lines (Fig. 1B). To
generate biological replicates, each pool was delivered in tripli-
cate infections. Genomic DNA was isolated from the infected
cells at early and late (2 weeks after puromycin selection) time
points. The assumption was that a synthetic lethal shRNA
should be depleted by the 2-week time point. We verified that
MYCN overexpression led to increased growth rates of GIMEN
cells as testified by cell growth assays and cell cycle analysis
using flow cytometry (Fig. 1, C and D). These results are in line
with previous reports in which MYCN overexpression was
shown to promote cancer cell proliferation (32, 33).
At the end of the screen, we identified 789 shRNAs depleted
in GIMEN-MYCN cells targeting 537 genes (supplemental
Data Set S1). To identify additional synthetic lethal shRNA, we
TABLE 1
Details of the shRNA sequences used for the knockdown of MYCN synthetic lethal genes
Target gene Sense sequence Oligonucleotide ID Barcode ID
CKS 1B GATGTGCTCTGTATCCAGA V2LHS_150603 OBS_BC_230698
AHCY CTCTCCTCCCTAAGAGCTA V2LHS_112026 OBS_BC_235827
BLM CTTCCTATGATATTGATAA V2LHS_89234 OBS_BC_217959
PKMY T1 CGTGTCTAATAAAAAGTAT V3LHS_644702
Nonsilencing control CTCGCTTGGGCGAGAGTAA RHS4346
MYCN Synthetic Lethal Genes in Neuroblastoma
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inspected 4,429 hairpins that were added in further releases of
theOpenBiosystem library, focusing on genes implicated in the
cell cycle. 60 genes were identified as involved in cell cycle reg-
ulation according to theGeneOntology analysis byDAVID (34,
35), and among these genes, 22 were previously identified as
potential MYC-regulated genes. The promoter sequences of the
38genesnot alreadyknowasMYCtarget geneswere inspected for
the presence of MYCN binding sites using Eukaryotic Promoter
DatabaseandTFSEARCH(36,37).According to this analysis, nine
genes containedpotentialMYCNbinding sites in their promoters.
Among these, we selected for further analysis PKMYT1 because
it is a cell cycle kinase similar toWEE1, whose inactivation was
previously demonstrated to be synthetic lethal to c-MYC (23,
38) (Fig. 1E).
Pathway analysis showed that the genes identified in the
screen are involved in regulation of cell survival, DNA replica-
tion and damage, cell cycle, and cellular movements (Fig. 2A).
According to the Myc Target Gene Database (39), several
knownMYC target genes score high in the list such as ABCE1,
BCL2L12, RBBP4, NAP1L1, EIF2S1, POLD1, BMP4, POLR2H,
SUCLG1, HNRPA1, BIRC6, and AHCYL1 (supplemental Data
Set S1). Notably, a number of the hits identified in our screen
are functionally related to theMYC synthetic lethal genes orga-
nized in three major hubs recently described by Grandori and
co-workers (29) on the basis of published RNAi screens. For
example, we detected genes involved in transcriptional initia-
tion and elongation (DDB1, BTAF1, TAF9B, TBPL1, and
POLR2H), transcription and theMYC/MAXnetwork (HDAC9,
FIGURE 1. Genome-wide shRNA screen. A, schematic representation of the shRNA screen strategy. B, Western blot analysis demonstrating MYCN overex-
pression in the cell line stably transfected with the MYCN expression vector. C, trypan blue dye exclusion assay illustrating the effect of stable MYCN overex-
pression onGIMEN-MYCN andGIMEN-EMPTY cells. Cells were counted at the indicated hours from the seeding point. The results represent themeans of three
experiments performed in triplicate. Error bars indicated standard errors. D, flow cytometry analysis showing the cell cycle profiles of GIMEN-MYCN and
GIMEN-EMPTY cells. E, strategy used to identify further synthetic lethal shRNAs based on new releases of the Open Biosystems pGIPZ-shRNAmir lentiviral
library.
MYCN Synthetic Lethal Genes in Neuroblastoma
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NR1I3,MED23, SAP130, andMYB) ubiquitin functions related
to the cell cycle checkpoint as well as kinases or other proteins
involved in this process (UBE3C, UBE2C, UBE20, UBE2T,
RAD21, PKMYT1, CKS1b, CUL2, FBXL7, FBX040, FBX015,
and FBX011) (supplemental Data Set S1 and Fig. 2B). Notably,
we also identified AURKA, a kinase critically required to stabi-
lize the MYCN protein and whose inactivation triggers syn-
thetic lethality in MYCN-amplified neuroblastomas (24).
Functional Significance of MYB, PKMYT1, CSK1B, AHCY,
and BLM in MYCN-amplified Neuroblastomas—The shRNA
that was most significantly dropped in MYCN positive
cells targeted the MYB gene, which encodes the c-MYB tran-
scription factor. This is notable, because we have recently
shown that the related memberMYBL2, encoding B-MYB, is a
direct target of MYCN and regulates the expression of the
MYCN amplicon in a positive regulatory loop. In that study, we
FIGURE 2. Bioinformatics analysis of synthetic lethal candidates identified with the shRNA screen. A, molecular and cellular functions of the candidate
genes. Fisher’s exact test was used as a scoring method, and the threshold was set at p 0.05. B, network analysis showing selected MYCN synthetic lethal
genes identified in the shRNA screen (blue) in relation to the network of MYC synthetic lethal genes identified in previous large scale screens (22, 23). The
clustering of the genes was adapted from Fig. 3 in Cermelli et al. (29), in which the following functional hubs were identified: (I) MYC-MAX network, (II)
components of transcription initiation and elongation complexes, and (III) genes involved in DNA damage repair and cell cycle checkpoints. Genes from the
ToyoshimaandKessler screens are depicted inblack. MYC synthetic lethal genes that intersect between the “core” genes forming a circle around theMYC-MAX
network and the Kessler screen are shown in dark green; those between the core and the Toyoshima screen are light green; those between Kessler and
Toyoshima are yellow; and those between our screen and Kessler’s are gray. Direct interactions are shown as dark green lines, and indirect interactions are light
blue.
MYCN Synthetic Lethal Genes in Neuroblastoma
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demonstrated that ablation of B-MYB triggers synthetic lethal-
ity in cells with amplified MYCN (40). Similarly to MYBL2,
MYB expression is significantly increased in MYCN-amplified
neuroblastomas predicting poor survival (Fig. 3, A and B). To
verify whether c-MYB is required for fitness ofMYCN-express-
ing cells, we infected GIMEN andGIMEN-MYCN cells with an
shRNA lentiviral vector targeting MYB and observed that this
caused massive activation of apoptosis in MYCN, but not non-
MYCN, expressing cells (Fig. 3C). From a clinical perspective,
MYB proteins are not optimal targets because small molecule
inhibitors specific for this class of transcription factors have not
been yet developed. To prioritize druggable genes and reduce
FIGURE 3.MYB expression is increased inMYCN-amplified tumors, predicts poor survival of neuroblastoma patients, and is required for survival of
MYCN-expressing cells. A, box plot showing expression of MYB in neuroblastoma tumors with (20 cases) or without (81 cases) MYCN amplification. B,
Kaplan-Meier analysis demonstrating a significant association of MYB expression with poor outcome of neuroblastoma patients. C, propidium iodide DNA
staining and flow cytometry analysis showing increased DNA fragmentation, diagnostic of apoptosis, in GIMEN-MYCN, compared with control, cells after
infection with aMYB shRNA lentivirus.
FIGURE 4.MYCN binds the PKMYT1 and BLM promoters in vivo. A, chromatin immunoprecipitation assays showing binding of MYCN in the region of the
PKMYT1 promoter containing a putative E-box in the proximity of the transcription start site. The binding was detected in theMYCN-amplified cell lines LAN1
and NB19 but not in the non-MYCN-amplified SHSY5Y cells. B, chromatin immunoprecipitation assays showing binding of MYCN in the region of the BLM
promoter containing a canonical E-box. Neg. cntr, negative control.
MYCN Synthetic Lethal Genes in Neuroblastoma
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FIGURE 5. Expression of AHCY, BLM, PKMYT1, and CKS1B correlates withMYCN expression. A, box plot visualizing themRNA expression of the different
genes in biopsies isolated fromneuroblastomaswith (20 cases) or without (81 cases)MYCN amplification. The datawere generated using the tools available in
theOncominewebsite.B, Kaplan-Meier survival curves in patientswithhigh (red line) or low (blue line) expressionofMYCN,AHCY,BLM, PKMYT1, orCKS1BmRNA
expression. The survival curves were generated using the Oncogenomics Neuroblastoma Prognosis database. C, Q-PCR analysis demonstrating relative levels
of gene expression in the GIMEN-EMPTY and GIMEN-MYCN cell lines. Gene expression was normalized relative to the expression of the housekeeping gene
GAPDH. The expression levels of thedifferent genes in the controlGIMEN-EMPTYcell linewere arbitrarily set to 1.Q-PCRswereperformed in triplicate. Error bars
indicate standard deviations.
MYCN Synthetic Lethal Genes in Neuroblastoma
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the number of candidates to a manageable number, we used the
following criteria: (a) the genes are, or have the potential to be,
directMYC targets; (b) the genes have prognostic value in neuro-
blastoma; and (c) inhibitors are readily available. We therefore
selectedAHCY, BLM, PKMYT1, andCKS1B for further analysis.
The adenosylhomocysteinase (AHCY) gene encodes S-
adenosylhomocysteine hydrolase (SAHH)2 that metabolizes
S-adenosyl homocysteine, an inhibitor of methylation reac-
tions. It was shown previously that AHCY is a direct c-MYC
target gene and that SAHH is critical for c-MYC metabolic
effects and tumorigenic activity (41). The SAHH inhibitor 3-
deazadenosine (3-DAZA) inhibits methylation reactions and
has been shown to possess antiretroviral activity in preclin-
ical experiments (42, 43).
CKS1B encodes a cyclin-dependent kinase binding protein
that plays a crucial role in cell-cycle regulation. CKS1B is
overexpressed inmanymalignancies including breast, prostate,
cervical cancers, nasopharyngeal carcinoma, and multiple
myeloma, where it promotes cell proliferation (44–49). CKS1B
is transcriptionally induced by c-MYC and negatively regulates
the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 in lym-
phoma, supporting c-MYC tumorigenesis (50). CKS1B has
been shown to overcome the DNA damage response barrier trig-
gered by activated oncoproteins, suggesting that in the context of
activated MYC its expression could enhance cancer cell fitness
2 The abbreviations used are: SAHH, S-adenosylhomocysteine hydrolase;
3-DAZA, 3-deazadenosine.
FIGURE 6.Down-regulation of AHCY, BLM, CKS1B, and PKMYT1 increases apoptosis and slows down the growth of neuroblastoma cells overexpress-
ing MYCN. A, apoptosis of GIMEN-EMPTY and GIMEN-MYCN cells infected with lentiviral vectors containing shRNAs targeting AHCY (shAHCY), BLM (shBLM),
PKMYT1 (shPKMYT1), CKS1B (shCKS1B), or scrambled control vector (shSCR) was determined by annexin V staining and flow cytometry. The error bars indicate
standard deviations, and statistical significance was assessed using Student’s t test. B, trypan blue dye exclusion assay showing effect of shRNA-mediated
knockdownofAHCY and BLM on the growth of GIMEN-EMPTY andGIMEN-MYCN cells. The results represent themeans of two independent experiments, each
performed in triplicate. Error bars indicate standard deviations. C, Q-PCR was used to assess gene expression in GIMEN/GIMEN-MYCN cells 1 week after
infections with shRNA lentiviral vectors targeting no gene (shSCR) or AHCY, AURKA, CKS1B, BLM, or PKMYT1 (shGENE). Gene expression levels in cells infected
with the control virus were set to 1. Q-PCRs were performed in triplicate. Error bars indicate standard deviation.
MYCN Synthetic Lethal Genes in Neuroblastoma
JANUARY 23, 2015•VOLUME 290•NUMBER 4 JOURNAL OF BIOLOGICAL CHEMISTRY 2205
 at B
RU
N
EL U
N
IV
 on February 16, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
(45). A small molecule inhibitor of CKS1B, fluoexetine (also
known as Prozac), is an antidepressant widely used in clinics.
PKMYT1 encodes a member of the serine/threonine protein
kinase family involved in cell cycle regulation. PKMYT1 inacti-
vates cell division cycle 2 protein (CDK1) by promoting Thr14
and Tyr15 phosphorylation in concert with the WEE1 kinase
(51). This phosphorylation event is critically required for pro-
gression of cells into mitosis. Ablation of WEE1 and PKMYT1
expression can cause mitotic collapse and apoptosis of cancer
cells (38, 52). A small molecule tyrosine kinase inhibitor,
PD166285, has been shown to inhibit PKMYT1 at lownanomo-
lar concentrations (53). The PKMYT1 promoter contains a
potential E-box sequence near the transcription start site. ChIP
assays confirmed that binding of MYCN could be detected in
the MYCN-amplified neuroblastoma cell lines NB19 and
LA-N-1, whereas it was absent in the non-MYCN-amplified
SHSY5Y cell line (Fig. 4A).
Bloom syndrome, RecQ helicase protein (BLM), is required
to maintain the intra-S-phase checkpoint, and its deregulation
may be important for cancer progression (54–57). People car-
rying mutations in the BLM gene are predisposed to different
types of cancer and have a shortened lifespan (58). Because
accelerated cell division imposed by activated MYC is associ-
ated with increased risk of replication errors andDNAdamage,
it is reasonable to postulate that cancer cells with activated
MYC are particularly sensitive to reduced RecQ helicases such
as BLMandWRN (59–62). Recently, smallmolecule inhibitors
of BLM have been developed that have shown anticancer activ-
ity in preclinical studies (63). Examination of the promoter of
the BLM gene revealed a canonical E-box (CACGTG) located
500 bp upstream from the transcriptional start site. We per-
formed ChIP analysis to demonstrate that MYCN binds to the
BLM promoter inMYCN-amplified LA-N-1 and NB19 neuro-
blastoma cells, whereas the binding was not detected in non-
MYCN-amplified SH-SY5Y cells (Fig. 4B).
The significance ofBLM,AHCY,PKMYT1, andCKS1B in the
pathogenesis of neuroblastoma is indicated by their elevated
expression inMYCN-amplified tumor samples and in MYCN-
overexpressing cells and their correlation with poor patient
survival (Fig. 5, A–C). To further validate the selected candi-
dates, we transduced GIMEN-EMPTY and GIMEN-MYCN,
with single pGIPZ-shRNAmir lentiviral vectors targeting
PKMYT1, AHCY, BLM, and CKS1B. After 11 days in culture,
GIMEN-MYCN cells infected with the shRNA targeting the
candidate genes weremore prone to apoptosis or growth arrest
than parental cells (Fig. 6, A and B). Interestingly, concurrent
inhibition of AHCY and BLM resulted in additive inhibition of
the proliferation of MYCN-expressing cells, suggesting that
targeting more than one gene at the time could have clinical
value (Fig. 6B). As expected, the shRNAs caused reduced gene
expression that varied between 90 and 50% in both cell lines
(Fig. 6C). To confirm that down-regulating the selected genes
has the potential to inhibit the survival and/or proliferation of
cells with natural amplification ofMYCN, we first assessed the
expression of PKMYT1, BLM, AHCY, and CKS1B at the pro-
tein and mRNA levels in a panel of MYCN-amplified and
nonamplified cell lines. We observed higher expression of the
genes inMYCN-amplified cells, in line with the hypothesis that
they are direct targets of MYCN (Fig. 7, A and B). Knockdown
of the genes caused a selective increase of apoptosis in the
majority of MYCN-amplified cells as opposed to cells with no
MYCN amplification, confirming that expression of PKMYT1,
BLM, AHCY, and CKS1B is crucial for the fitness of cells with
activatedMYC (Fig. 8, A and B).
BLM Limits the Oncogenic Stress and PKMYT1 Regulates
MYCN Protein Levels in MYCN-amplified Neuroblastoma Cell
Lines—It has been reported that inhibition of BLM leads to
increased DNA double-stranded breaks and apoptosis of can-
cer cells (54, 63). To verify the role of BLM in neuroblastoma,
we examined the expression of phosphorylated histone
-H2AX, used as a marker for DNA double-stranded breaks,
after infection of neuroblastoma cells with a BLM shRNA. We
observed that ablation of BLM expression caused increased
expression of the -H2AX marker inMYCN positive cell lines
(Fig. 9A). Depletion of PKMYT1 caused a drastic reduction of
MYCNprotein inmost of the neuroblastoma cell lines analyzed
(Fig. 9B). This is consistent with the role of cdk1 as a kinase
required to prime MYCN for proteosomal degradation (24).
We hypothesized that ablation of PKMYT1 promotes cdk1/
GSK3-mediated phosphorylation and degradation of MYCN.
Indeed, the PKMYT1 inhibitor PD166285 caused increased
phosphorylation of MYCN at threonine 58 followed by sharp
degradation of theMYCNprotein that did not required de novo
protein synthesis (Fig. 9,C andD). As a control, we verified that
FIGURE 7. SAHH, BLM, CKS1B, andPKMYT1are highly expressed in naturallyMYCN-amplifiedneuroblastoma cell lines.A, Western blot showing SAHH,
BLM, PKMYT1, and CKS1B protein expression in a panel ofMYCN-amplified and nonamplified Neuroblastoma cell lines. Actin was used as a loading control. B,
Q-PCR demonstrating relative gene expression levels in the MYCN positive or negative Neuroblastoma cell lines. Gene expression levels in the non-MYCN-
amplified cell line GIMENwas arbitrarily set to 1, andGAPDH expressionwas used for normalization. The error bars indicate standard deviation. *, p 0.005; **,
p 0.001 (Student’s t test n 3).
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MYCNmRNA levels were unchanged after the treatments, rul-
ing out an effect on gene expression (Fig. 9E).
PD166285 and 3-DAZACause Selective Apoptosis ofMYCN-
amplified Cells—To assess whether chemical inhibitors of
PKMYT1 and SAHH have the potential to destabilize the fit-
ness of MYCN-amplified cells inducing synthetic lethality, we
used PD166285 and 3-DAZA in survival assays. We observed
that the compounds inhibited the growth of bothMYCN posi-
tive and negative neuroblastoma cells. However, the drugs
selectively killed MYCN positive cells (Fig. 10, A–D). Analysis
by propidium iodideDNAstaining and flow cytometry revealed
that the drugs caused apoptosis of MYCN-positive, but only
growth arrest in the G1 phase of the cell cycle ofMYCN-nega-
tive cells (data not shown).
FIGURE 8.SAHH,BLM,CKS1B, andPKMYT1are important for survival ofMYCN-amplifiedneuroblastoma cell lines.A, apoptosis assaywas carried out as
indicated in Fig. 6A. The error bars indicate standarddeviations, and statistical significancewas assessedusing Student’s t test.B, Q-PCRwasused to assess gene
expression in naturally MYCN-amplified neuroblastoma cell lines 1 week after infection with shRNA lentiviral vectors targeting no gene (shSCR) or AHCY,
AURKA, CKS1B, BLM, or PKMYT1 (shGENE). Gene expression levels in cells infectedwith the control viruswere set to 1. Q-PCRswere performed in triplicate. Error
bars indicate standard deviation.
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Concurrent Targeting of PKMYT1, SAHH, BLM, and AHCY
as a Possible Therapeutic Approach for MYC-driven Tumors—
Combination therapy in whichmultiple pathways are inhibited
at the same time should be advantageous because the cancer
cell cannot rely on alternative mechanisms of survival. A fur-
ther advantage of pharmacological combinations is that the
FIGURE 9. Knockdown of BLM and PKMYT1 induces genomic stress and destabilize MYCN protein in neuroblastoma cell lines. A, Western blot analysis
showing the expression of the indicated proteins after infection of a panel of MYCN-amplified (NB19, SMS-KCNR, IMR32, or SK-N-BE(2)) or nonamplified
(GI-M-EN, SK-N-AS, or SH-SY5Y) cells with control or BLM shRNA lentiviruses. B, Western blot analysis showing the expression levels of MYCN after shRNA-
mediated knockdown of PKMYT1 in the panel of MYCN-amplified and nonamplified neuroblastoma cells. Expression of Actin was used as a loading control. C,
Western blot analysis showing the expression of phosphorylated MYCN (p-MYCN) and total MYCN in the neuroblastoma cell lines IMR-32 and NB19 treated
with PD166285. Cell lysateswere prepared at the indicated timepoints. Expression of Actinwas used as a loading control.D, Western blot analysis showing the
expression of MYCN in NB19 cells after treatment with PD166285 with or without cycloheximide (CHX) or DMSO vehicle. Actin was used as a loading control.
E, Q-PCR analysis demonstrating unchanged levels of MYCNmRNA after treatment of NB19 cells with PD166285. Bars indicate themeans of two independent
experiments, each performed in triplicate. Error bars indicate standard deviations.
FIGURE10.PD166285and3-DAZAtriggersynthetic lethality inMYCN-amplifiedcells.Nonamplified(AandC)andMYCN-amplified(BandD)neuroblastomacells
were exposed toPD166285 and3-DAZAas indicated. Live/death cellswereharvested and counted at the indicated times. Thebars indicate themeanvalues of three
independent experiments, each performed in triplicate. Error bars indicate standard deviations. *, p 0.05; **, p 0.01 (Student’s t test n 3).
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concentration of each agent is lower than that required as a
single drug, enhancing specificity and reducing toxicity. We
tested the killing effect of PD166285, 3-DAZA, and inhibitors of
BLM and CKS1B (ML216 and fluoxetine, respectively). When
used as single agents at lowmicromolar (3-DAZA,ML216, and
fluoexetine) or nanomolar (PD166285) concentrations, the
drugs were ineffective or only caused a marginal inhibition of
cell proliferation. Combining the drugs caused profound inhi-
bition of proliferation of all neuroblastoma cell lines, indepen-
dently from MYCN expression. However, a significant killing
effect of the drugs was only observed inMYCN-amplified cells
(Fig 11, A and B).
DISCUSSION
Oncogenic transcription factors are notoriously difficult to
target therapeutically, and the hypothesis that we tested in
this investigation is whether subverting a MYCN-dependent
genetic program could be used as a strategy in treating cancers
driven by this protooncogene. To identify key genes and path-
ways required for survival of cancer cells with activated MYC,
FIGURE 11. Combinations of small molecule inhibitors targeting theMYCN interactome suppress neuroblastoma cell proliferation and induce selec-
tive killing of MYCN-amplified cells. Nonamplified (A) and MYCN-amplified (B) neuroblastoma cell lines were exposed to Flouxetine, ML216, 3-DAZA, and
PD166285 alone or in combination as indicated. Live/death cells were harvested at the indicated times. The results represent themeans of three independent
experiments, each performed in triplicate. Error bars indicate standard deviations. *, p 0.01; **, p 0.001 (Student’s t test).
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we carried out an shRNA genome wide drop-out screen in can-
cer cell lines with or without expression of MYCN. Using this
method, we identified hundreds of shRNAs depleted inMYCN-
expressing cells that mainly inactivate genes involved in tran-
scription, cell cycle, and apoptosis. The result of our analysis is
consistent with previous RNAi screens in which genes synthet-
ically lethal to c-MYC have been identified inmammalian cells.
The Grandori laboratory has recently integrated the results of
two major RNAi screen identifying three main hubs. The first
hub includes genes involved in transcription initiation and
elongation complexes; the second highlights both positive and
negative regulators connected to the MYC/MAX network; the
third hub includes kinases, ubiquitin, and sumoylation func-
tions related to cell cycle checkpoint and DNA repair (29). Sev-
eral of theMYCN synthetic lethal genes identified in our screen
appear to be related to each of these hubs, in line with the
hypothesis that MYCN and c-MYC functions are overlapping,
and their role is mainly defined by different spatial and tempo-
ral physiopathological contexts. To prioritize interesting can-
didates, we havemanually selected four genes that responded to
the following criteria: (a) are directMYC targets, (b) have prog-
nostic value, and (c) are druggable. The genes selected for
further analysis were AHCY, PKMYT1, CKS1B, and BLM.
PKMYT1 is a serine-threonine kinase that in concert with
WEE1 phosphorylates and inactivates cdk1 complexed with
cyclinB, regulating entry into mitosis. Interestingly, theMYCN
protein is destabilized by phosphorylation of serine 62 by the
cdk1/cyclinB kinase required to prime phosphorylation of thre-
onine 58 by gsk3b, initiating proteasomal degradation (24).We
showed here that PKMYT1 is required to stabilize the MYCN
protein in neuroblastoma cells by reducing T58 phosphoryla-
tion by the cdk1/gsk3 kinases, explaining the synthetic lethal
effect of PKMYT1 inactivation in MYCN-amplified cells.
CKS1B is overexpressed in several cancers and binds to cdk2,
overcoming the replicative barrier imposed by activated onco-
proteins. DNA replication stress induced by oncogenes such as
Cyclin E or c-MYC can activate an intra-S-phase checkpoint
that induces accumulation of inactive cdk2. CKS1B can over-
ride the intra-S-phase checkpoint by restoring cdk2 activity
(45). Interestingly, inactivation of cdk2 has been previously
shown to promote synthetic lethality in cells with amplified
MYCN, confirming the relevance of this pathway for MYC
tumorigenesis (64). BLM is similar to the Werner DNA heli-
case, WRN, required to limit replication stress imposed by
accelerated S-phase imposed by activated oncogenes, including
c-MYC (60, 61). Our results support the hypothesis that BLM is
critical for the survival ofMYCN-amplified cells because it lim-
its DNA damage promoted by oncogenic activation, as sug-
gested by the induction of phosphorylated histone -H2AX in
MYCN-amplified cells after depleting BLM expression.
The majority of metastatic, high risk neuroblastomas are
characterized by the presence of MYCN amplification. These
highly proliferative tumors are treated with chemotherapeutic
drugs that are potentially damaging and highly toxic in chil-
dren. Dissecting the pathways required by cancer cells to toler-
ate oncogenic stress imposed by activated MYC potentially
allows identification of druggable targets that would lead to a
more specific and less toxic therapeutic treatments for MYC-
driven tumors. To establish, as a proof of principle, that drug-
ging theMYCNnetwork has clinical value, we have used readily
available small molecule inhibitors of BLM, CKS1B, PKMYT1,
and SAHH. The compounds, either alone or in combination,
caused death in themajority ofMYCN-amplified cells, suggest-
ing that clinically viable derivatives of these compounds could
be used to treat high risk neuroblastomas and other tumors
driven by MYC. Of course, the effects of the small molecule
inhibitors will need to be validated in appropriate neuroblas-
toma mouse models prior to any potential clinical application.
Mathematical modeling demonstrates that the simultaneous
treatment of cancer cells with drugs targeting multiple path-
ways can improve patients outcome, avoiding drug resistance
(65, 66). Our observation that combining pharmacological con-
centrations of drugs targeting the MYCN network can activate
synthetic lethality inMYCN-amplified tumor cells suggests that
this approach has the potential to be successfully translated in
the clinic.
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